To further verify the impact of antibody-based inhibition of plasma ASM activity on AD pathologies, 6-month-old WT or APP/PS1 mice were immunized with a recombinant ASM peptide in adjuvant or adjuvant containing a peptide vehicle (PBS) 4 times until 9 months of age. This evidence concerns the gene APP and Alzheimer disease.